glp 1 and pancreas GLP-1 Agonists Pancreatitis Risk GLP-1 Medications – Community Education
Description
This update underscores both the promise and the complexity of advancing oral GLP-1 drug technology, highlighting ongoing industry efforts to balance innovation, safety and patient-centric design as companies work to meet evolving global treatment needs
Reproductive Biomedicine Online, 59 (2), 255267
Rosenstock J, Hansen L, Zee P, et al
Following the promising results of Bay 27-9955, several glucagon receptor antagonists have been developed however when administered over a longer period, have been met with several adverse effects including increased plasma alanine aminotransferase (ALT), LDL-cholesterol in addition to increased blood pressure and body weight (52)
The treatment implications differ based on which mechanism is responsible
Not just a little, but enough to entirely shift someone's risk profile within at least 6 months of using them
